Cargando…

Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial

Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viscusi, Eugene R., Torjman, Marc C., Munera, Catherine L., Stauffer, Joseph W., Setnik, Beatrice S., Bagal, Sukirti N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504812/ https://www.ncbi.nlm.nih.gov/pubmed/33982405 http://dx.doi.org/10.1111/cts.13042

Ejemplares similares

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
por: Shram, Megan J., et al.
Publicado: (2021)

Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
por: Fishbane, Steven, et al.
Publicado: (2022)

Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis
por: Spencer, Robert H., et al.
Publicado: (2023)

Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2020)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
por: Weiner, Daniel E., et al.
Publicado: (2022)

Difelikefalin: A Novel Therapy for Dialysis Patient Care
por: Watnick, Suzanne, et al.
Publicado: (2022)

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
por: Greedy, Benjamin M., et al.
Publicado: (2013)

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2012)

Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
por: Topf, Joel, et al.
Publicado: (2022)

Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review
por: Wala, Kamila, et al.
Publicado: (2022)

Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors
por: Neubert, John K, et al.
Publicado: (2007)

Novel Kappa-Opioid Receptor Agonist for the Treatment of Cholestatic Pruritus: Systematic Review
por: Bailey, Adrian Joseph Michel, et al.
Publicado: (2022)

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
por: Stark, Jeffrey G., et al.
Publicado: (2023)

nor-BNI Antagonism of Kappa Opioid Agonist-Induced Reinstatement of Ethanol-Seeking Behavior
por: Harshberger, Erin, et al.
Publicado: (2016)

Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation
por: Shokirova, Hurramhon, et al.
Publicado: (2021)

Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold
por: Reed, Brian, et al.
Publicado: (2022)

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis
por: Viscusi, Eugene R., et al.
Publicado: (2016)

Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist
por: Beck, Tyler C., et al.
Publicado: (2019)

Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic
por: Inan, Saadet, et al.
Publicado: (2021)

Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
por: Mititelu Tartau, Liliana, et al.
Publicado: (2021)

Blood–brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists
por: Viscusi, Eugene R, et al.
Publicado: (2020)

Pharmacological profiles of opioid ligands at Kappa opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2006)

Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral Pain
por: Hughes, Jr, Francis M., et al.
Publicado: (2013)

Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice
por: Paton, Kelly F., et al.
Publicado: (2022)

Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain
por: Viscusi, Eugene R.
Publicado: (2019)

Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial
por: Narita, Ichiei, et al.
Publicado: (2022)

Cardioprotection by kappa-opioid receptor agonist U50488H is mediated by opioidergic regulation but not by calcium current modulation
por: Chun, Kook Jin, et al.
Publicado: (2010)

The Differential Effects of a Selective Kappa-Opioid Receptor Agonist, U50488, in Guinea Pig Heart Tissues
por: Hung, Chi-Feng, et al.
Publicado: (2015)

Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion
por: Chen, Chongguang, et al.
Publicado: (2022)

Discovery of 7-Azanorbornane-Based Dual Agonists for the Delta and Kappa Opioid Receptors through an In Situ Screening Protocol
por: Karaki, Fumika, et al.
Publicado: (2023)

Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial
por: Mendelson, John E., et al.
Publicado: (2010)

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Kappa opioid receptor agonists improve postoperative cognitive dysfunction in rats via the JAK2/STAT3 signaling pathway
por: Li, Xi, et al.
Publicado: (2019)

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
por: Wang, Xin, et al.
Publicado: (2021)

Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]
por: Assadi, Seyed Mohammad, et al.
Publicado: (2003)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Structure of the human kappa opioid receptor in complex with JDTic
por: Wu, Huixian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8r2v3kv5k1259chjb0f0f59ppo